Seeking Alpha

More on Novartis (NVS) Q4: Adjusted profit +3% to $3.1B. Net profit +74% to $2.05B, below...

More on Novartis (NVS) Q4: Adjusted profit +3% to $3.1B. Net profit +74% to $2.05B, below consensus of $2.38B. Last year was affected by writedowns. Pharmaceutical division sales flat at $8.3B, Diovan sales -25% to $992M after loss of patent protection. Shares +2.4% in Zurich.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|